Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chromium edetate
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Chromium edetate is a diagnostic radiopharmaceutical used to determine glomerular filtration rate (GFR) in the assessment of renal function. It consists of radioactive Chromium-51 chelated with ethylenediaminetetraacetic acid (EDTA). When administered intravenously, it allows for the measurement of kidney filtration capacity by tracking its clearance from the bloodstream.
- Other names
- Chromium Cr 51 edetateChromium EDTAChromium-51 EDTAChromium51 EDTAChromium 51 EDTACr 51-ethylenediamine tetraacetic acidCr51-ethylenediamine tetraacetic acidCr-51-ethylenediamine tetraacetic acidCr 51-EDTACr51-EDTACr-51-EDTA
Beyond the preview
Go deeper on chromium edetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chromium edetate.